A UCLA-led team has described how they advanced an experimental CRISPR approach for sickle cell disease into a blood stem cell therapy that can be manufactured at the scale and quality required for a clinical trial. The study was published…
“My hope is that one day Origin Genomics can help couples and families with these hereditary diseases not pass them down to their children, and still have as many healthy children as they’d like,” Tie said, according to the Origin…
Verismo Therapeutics, the US subsidiary of South Korea's HLB Innovation (024850.KQ), said on the 5th that its CAR-T therapy SynKIR-310, targeting relapsed or refractory B-cell non-Hodgkin lymphoma, recorded an objective response rate (ORR) of 80% and a complete response (CR) rate of…
Michael Dickinson, Hematologist at Peter MacCallum Cancer Centre, shared on X: “CAR T-cell therapy referral and uptake in relapsed/refractory large B-cell lymphoma: US claims analysis (Komodo Health, Oct 2016 to May 2025), 8959 adults after 2 or more prior lines. It’s just a reality…
News-Medical UCLA advances CRISPR gene-editing therapy for sickle cell disease A UCLA-led team has described how they advanced an experimental CRISPR approach for sickle cell disease into a blood stem cell therapy that can be manufactured at the scale and…
Research examines a self-reinforcing resistance niche created by extracellular chromatin released during CAR T-cell killing and its reversal by DNase I Presentation selected for ASH scientific session focused on overcoming resistance in CAR T-cell therapy The research will be featured…
Nov 03, 2026, 19:00 ET SynKIR™-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based single-chain CAR T in preclinical models Preclinical in vivo data showed reduced exhaustion of tumor-infiltrating SynKIR™-110 T cells…
RegMedNet is part of Taylor & Francis Group. Original story from the National University of Singapore Yong Loo Lin School of Medicine (Nus Medicine; Singapore, Singapore). Researchers identify DUSP4 as a protein that could enhance CAR-T cell therapy, offering new hope for…
Yahoo Finance Oops, something went wrong Tessera Therapeutics to Present New Preclinical Data Supporting its In Vivo Sickle Cell Disease Program and In Vivo CAR-T Applications at the 68th American Society of Hematology Annual Meeting SOMERVILLE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tessera…
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment. Gene therapy can eliminate severe vaso-occlusive crises without resolving the chronic pain a patient has lived with for years.
CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up.
An article joins this feed when it matches these terms. Each one is also a search of its own.